Related Experiment Video

Updated: May 17, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling

Xiaoying Zhang1, Christopher Szeto, Erhe Gao

  • 1Cardiovascular Research Center, Department of Physiology, Temple University School of Medicine, Philadelphia, PA 19140, USA.

Circulation Research
|October 30, 2012
PubMed
Abstract

Insights

Selective inhibition of protein kinase A (PKA) prevents heart failure by blocking PKA-dependent cell death pathways and revealing PKA-independent cardioprotection, offering a novel therapeutic strategy.

Area of Science:

  • Cardiovascular Research
  • Molecular Cardiology
  • Pharmacology

Background:

  • Persistent β-adrenergic receptor activation in heart failure contributes to myocyte death via protein kinase A (PKA)-dependent and independent pathways.
  • β-adrenergic signaling also activates cardioprotective mechanisms, suggesting a dual role.

Purpose of the Study:

  • To investigate the role of PKA in β-adrenergic receptor-induced cell death and cardioprotection using a novel PKA inhibitor peptide.
  • To test the hypothesis that PKA-dependent pathways mediate cell death and PKA-independent pathways mediate cardioprotection.

Main Methods:

  • Utilized PKA inhibitor peptide transgenic mice and cultured adult feline ventricular myocytes.
  • Administered chronic isoproterenol and β1-adrenergic receptor agonists.
  • Assessed cardiac hypertrophy, fibrosis, apoptosis, cardiac function, and intracellular calcium handling.

Main Results:

  • PKA inhibition prevented isoproterenol-induced cardiac dysfunction, hypertrophy, fibrosis, and apoptosis in mice.
  • Inhibition of PKA protected myocytes from agonist-induced death by preventing calcium overload and calcium/calmodulin-dependent kinase II activation.
  • Revealed a cardioprotective β-adrenergic signaling pathway (cAMP/exchange protein directly activated by cAMP/Rap1/Rac/extracellular signal-regulated kinase) upon PKA inhibition.
  • Selective PKA inhibition demonstrated superior protection post-myocardial infarction compared to β-blocker therapy.

Conclusions:

  • Selective blockade of PKA emerges as a potential novel therapeutic approach for heart failure.
  • Targeting PKA offers a promising strategy to mitigate cardiac damage and improve function in failing hearts.

More Related Videos

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart09:38

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart

Published on: May 19, 2017

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...